Supreme Court abortion case puts FDA regulation at risk

The Supreme Court Wednesday agreed to consider two abortion drug cases that, according to the federal government, former FDA commissioners, and biopharmaceutical industry leaders, could have a significant impact on FDA’s ability to regulate medicines.

The justices will be asked to determine whether physicians who have only a hypothetical link to women who have received mifepristone have standing to challenge FDA’s regulatory decisions in court. They will also be asked to determine if federal courts should have the power to second-guess FDA’s scientific and medical decisions about mifepristone. ...